Medico Remedies Limited, incorporated in 1994 and based in Mumbai, India, began as a Private Limited Company (Medico Remedies Private Limited) on March 18, 1994, and later converted to a Public Limited Company on March 6, 2017.
The company is a pharmaceutical formulation manufacturing and marketing enterprise with a strong focus on a wide range of therapeutic areas including antibiotics, anti-infectives, beta-lactams (penicillin, cephalosporins), antifungals, antimalarials, antiretrovirals, anti-ulcer drugs, antacids, vitamins & supplements, hematinics, and other critical medicines. Medico Remedies operates two manufacturing units in Palghar, Maharashtra: a general formulations unit and a specialized beta-lactam unit, further divided into penicillin and cephalosporin segments.
Medico Remedies offers an extensive product range across various therapeutic segments. This includes:
- Antibiotics and Anti-infectives
- Beta-Lactams (Penicillins and Cephalosporins)
- Antifungals
- Vitamins and Supplements
- Cardiovascular products
- Antipyretic, Analgesic, and NSAIDs medicines
- Antacid and Anti-ulcer drugs
- Antidepressants, Antipsychotics, and Anti-epileptics
- Antimalarials
- Dry Syrups
- Ointments and Creams
- Anti-diabetics
- Syrups
- Miscellaneous products, Diuretics, Antiretrovirals, and Steroidal preparations.
The product portfolio also encompasses NSAIDs, antihistamines, cardiovascular drugs, antipyretics, analgesics, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments, and creams/gels. The company is ISO 9001:2015 certified for its management system in the manufacture and marketing of pharmaceutical products, underscoring its commitment to quality. Medico Remedies also exports its products, signifying its presence in international markets.
Medico Remedies Ltd holds a market capitalization of ₹346.71 Crore as of July 2, 2025. According to Value Research classification, it is categorized as a Small Cap company. The stock has demonstrated growth, with a return of 34.73% in the last 3 years and a significant long-term appreciation of 171.49% on BSE over the same period.
For the full year ended March 2025, the company reported a net profit of ₹10.09 crore, an increase of 21.71% compared to ₹8.29 crore in March 2024. Sales for the year ended March 2025 rose by 4.15% to ₹150.94 crore, up from ₹144.92 crore in the previous year.
In the quarter ended March 2025, net profit increased by 40.00% to ₹4.34 crore, compared to ₹3.10 crore in the corresponding quarter of the previous year (March 2024). Sales experienced a marginal decline of 0.05% to ₹41.30 crore in Q4 FY2024-25.
For the quarter ended December 2024, net profit rose by 80.69% to ₹2.62 crore, from ₹1.45 crore in the quarter ended December 2023. Sales increased by 32.65% to ₹39.49 crore in Q3 FY2024-25.
- Operating Revenue (TTM): ₹150.96 Crore
- Annual Revenue Growth: 2%
- Pre-Tax Margin: 8%
- ROE (Return on Equity): 15%
- P/E (Price-to-Earnings) Ratio: 34.36
- P/B (Price-to-Book) Ratio: 6.62
- Debt Status: The company is debt-free, indicating a strong balance sheet that supports stable earnings growth.
- 52-Week High: ₹79.83
- 52-Week Low: ₹35.67
- P/B Ratio (as of 03-Jun-2025): 7.04 times (a 27% premium to peers' median of 5.56 times)
- P/E Ratio (as of 03-Jun-2025): 43.58 times (a 15% premium to peers' median of 38.05 times)
In May 2025, Medico Remedies commenced work on a new ₹30 Crore factory dedicated to antibiotics, which is projected to add ₹25 Crore in revenue over two years. This expansion signifies strategic initiatives to support future growth and manufacturing capacity.
- Promoter Holding: Decreased to 63.8% as of March 2025.
- Recent Promoter Activity: Promoter Haresh Mehta sold 3.5 lakh shares, reducing his stake to 20.22% on June 19, 2025. This indicates some reduction in promoter stake observed in recent quarters.
The company has demonstrated a sales growth of 11.2% over the past five years, suggesting moderate historical revenue expansion. However, its net income has grown at an impressive yearly rate of 43.64% over the last 5 years, significantly outperforming the industry average of 20.11% and indicating strong profitability improvement despite modest revenue growth.
From an O'Neil Methodology perspective, the stock has an EPS Rank of 83, which is a GOOD score reflecting consistent earnings. While some technical parameters might be lagging, its strong earnings profile warrants further examination.
Medico Remedies operates within the dynamic healthcare pharmaceutical sector. The company's strategy continues to focus on expanding manufacturing capabilities and maintaining its position across diverse therapeutic segments. The recent factory expansion, coupled with a robust balance sheet, positions the company for potential future growth in the pharmaceutical formulations market.
